Loading stock data…
$4.00-0.13 (-3.15%)
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. in the Healthcare sector is trading at $4.00 with a market capitalization of $596M. Wall Street consensus targets $9.33 (9 analysts), implying a +133.3% move over the next 12 months. The stock is currently 44% below its 52-week high of $7.18, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.82M↓ | $14.45M↑ | $13.02M↑ | $12.81M↑ | $10.00M |
| Gross Profit | $9.80M↓ | $10.98M↑ | $7.18M↓ | $8.30M↑ | $5.44M |
| Operating Income | -$8.22M↓ | -$4.20M↑ | -$28.84M↓ | -$11.48M↓ | -$11.37M |
| Net Income | -$22.86M↓ | -$8.06M↑ | -$31.86M↓ | -$15.45M↓ | -$13.55M |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of b...